Abstract
Bladder cancer (BCa) is a common malignancy, with about 81,190 estimated new cases and 17,240 estimated deaths in the United States in 2018 (1). Neoadjuvant cisplatin-based combination chemotherapy (NAC) followed by radical cystectomy (RC) with bilateral pelvic lymph node dissection is currently considered the standard of care in muscle-invasive bladder cancer (MIBC) patients (2). However, 5 years survival after surgery is approximately 50% (3). In this regard, adjuvant cisplatin based-chemotherapy (AC) improves survival outcomes and should be administered in medically fit, NAC naive patients with pT3/4 and/or positive nodes diseases at RC (2).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
